
Genitourinary Cancers
Latest News
Latest Videos

CME Content
More News

With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Urologists who are members of LUGPA are doing the right thing by being part of large group practices.

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA










While Laszewski said the Affordable Care Act (ACA), which is driving many of the changes, may end up being altered, he doesn't expect the program to be disbanded due to the political shift in legislative power.

In attending the Society of Urologic Oncology's annual meeting in Bethesda in early December, I was struck by the number of presentations focusing sharply on the burgeoning fields of biomolecular markers and immunotherapy and their application to urologic oncology.

Entrepreneur James Feldman, chief innovation officer of the Chicago-based company Shift Happens!, calls himself "a doctor for business."

Urologists hear quite a bit about risk from the legislative and regulatory angles.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses recent updates in bladder cancer treatment.





From a limited first meeting in the late 1990s that included the leaders of a dozen large group practices, LUGPA has grown so much that its annual meeting this November will include up to 550 physicians and 200 administrators, filling the organization's usual Chicago venue to capacity and necessitating a move to a larger space next year.

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).





















































